While at the University of Toronto, we saw early on how machine learning and convolutional neural networks could be applied for image recognition. We founded Atomwise after we proved the concept that the same technology could be applied to drug discovery by performing computational screens to find molecules worth testing in the lab.
Building on this early successs we've expanded the robustness of our models through early collaborations with our academic (AIMS program) and biopharma partnerships. Our technology now scales to screening billions of molecules for multiple projects simultaneously. We now use AI as a robust engine for drug discovery resulting in jointly held assets and our wholly owned pipeline to address previously undrugged diseases.